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phosphoenolpyruvate decarboxylase [42] , to name a few. However, excessive and prolonged exposure to Mn may lead to a neurological disorder that shar es many similarities with Parkinson's disease (PD), and is referred to as manganism [15] . Exposure to Mn in the general population occurs from the automo bile combustion of gasoline containing methylcyclo pentadienyl manganese tricarbonyl (MMT) or from organic Mncontaining pesticides, such as manga nese ethylenebisdithiocarbamate [8] . Chronic expo sure to high levels of inhalable Mn (15 mg Mn/m 3 ), which is commonly associated with several occupa tions (e.g. mining, battery manufacturing, welding, ferroalloy smelting, and steel production), is believed to be the most frequent cause of Mn neurotoxicity [32] . Individuals with some medical conditions such as liver failure or total parenteral nutrition exhibit elevated Mn blood level and neurological dysfunc tions [1] . The accumulation of Mn in basal ganglia is responsible for a form of parkinsonism with clinical features overlapping with, but distinct from, those observed in idiopathic PD [18] . Manganeseinduced neurotoxicity affects mainly the globus pallidus as well as the cortex and hypothalamus [48, 50] , distinct from the striatal changes associated with PD. Exces sive Mn deposition in the central nervous system (CNS) contributes to the pathogenesis of PD, causing loss of dopamine in the striatum, death of nondo paminergic (DAergic) neurons in the globus pallidus, and damage to glutamatergic and GABAergic pro jections [25, 39] . Manganese has also been shown to mediate fibril formation by αsynuclein along with its expression and aggregation [47] . A role for Mn has also been advanced in the etiology of a few neu rodegenerative disorders, e.g. Huntington's disease, amyotrophic lateral sclerosis, prion diseases and Alzheimer's disease (AD), all of which rely on similar intracellular mechanisms involving oxidative stress, mitochondrial impairment, and protein aggregation.
Mitochondrial dysfunction was found to be a com mon effect in Mn toxicity [7] . A previous study showed that primary astrocytic cultures are highly sensi tive to Mn and undergo apoptotic cell death involv ing mitochondrial dysfunction [51] . Manganese was found to be preferentially and rapidly transported into the mitochondrial matrix via the calcium (Ca 2+ ) uniporter, with relatively slow clearance, leading to the accumulation of Ca 2+ [16] . Elevated matrix calci um increases formation of reactive oxygen species (ROS) by the electron transport chain and mediates inhibition of aerobic respiration [22] . Manganese was found to induce mitochondrial respiratory dysfunc tion in vitro, induce ROS, and inhibit the antioxidant system by depleting glutathione and glutathione peroxidase [26, 52] . Additionally, activation of oxida tive stresssensitive kinases and transcription factors including nuclear factor (NF)κB has been identified in cell lines exposed to Mn [31, 51] .
Manganese-mediated dysfunction of astrocytes and astrocyte-neuron integrity
Astrocytes play an essential role in the CNS by regulating and maintaining the extracellular envi ronment and protective barriers, which include glia scars, the glia limitans and the bloodbrain barrier. Astrocytes ensure trophic, energy and metabolic support to neurons. Glial cells actively participate in neuronal excitability and survival by modulating synaptic homeostasis and formation [38] . Astrocytes accumulate Mn up to 50fold greater than neurons through a highaffinity transport mechanism [2] and hence are considered as an initial target for Mnin duced neurotoxicity. Chronic overexposure to Mn is associated with glial cell activation and is manifest ed with gliosis. As in neurons, albeit at higher con centrations, Mn is sequestered in mitochondria and disrupts astrocytic energy metabolism [6] . Impor tantly, the level of glutathione (GSH), the main cellu lar antioxidant, is significantly lower in neurons than in astrocytes. In general, neuronal stores of GSH are largely dependent upon astrocytic stores, and neu rons are more sensitive than astrocytes to oxidative stress [33] . Several studies have demonstrated that Mn promotes failure of astrocytes to maintain anti oxidant defense mechanisms via disruption of GSH synthesis [49] . In vivo, interneuron injury in striatal and pallidal regions of Mnexposed mice is associat ed with an increased number of reactive astrocytes expressing inducible form of nitric oxide synthase (iNOS) in the same brain areas [41] . Treatment of astrocytes with Mn increases uptake of Larginine, an iNOS substrate, leading to increased ROS genera tion as a consequence of nitric oxide (NO) production and deterioration of cellular antioxidant capacity and energy metabolism. Furthermore, as discussed below, Mn is believed to exert toxicity via disruptive effects on the synthesis of neurotransmitters. While Mn, at higher concentrations than in neurons, might be toxic to astrocytes themselves and the astrocytes are crucial for its brain transport and accumulation, they are extremely important from a neuroprotec tion point of view. For example, Mninduced neuro nal injury in the striatum and the globus pallidus is associated with primary dysfunction of astrocytes via mechanisms involving NO [45] . In addition, Mn inhibits the ability of astrocytes to promote neuronal differentiation by a mechanism that involves oxida tive stress and a reduction of the extracellular matrix protein, such as fibronectin [17] .
Glutamine in general and in the glutamine/glutamate-γ-aminobutyric acid cycle Glutamine (Gln) content in the extracellular fluid (microdialysates) (ECF) or in the cerebrospinal fluid (CSF) (~0.51 mM) exceeds, by at least one order of magnitude, the extracellular contents of other amino acids in these compartments. Glutamine is the most abundant amino acid in the plasma (at 600800 μmol) and exhibits extremely rapid cellular turnover rates [9, 10] . This amino acid serves multiple roles in the mammalian brain: as an essential precursor in nucle otide, glucose and amino sugar biosynthesis, gluta thione homeostasis and protein synthesis. Glutamine transport across cell membranes has been extensively studied. In the past few years a number of glutamine carriers have been cloned, and their molecular and functional properties have been characterized. Gluta mine transport systems in the mammalian brain are classified into two distinct groups termed sodiumde pendent (systems A, ASC and N) and sodiuminde pendent (system L). All of the glutamine transport systems has been identified in brain, indicating that the CNS possesses multiple pathways for Gln trans portation across the plasma membrane [5] .
In the mammalian brain, Gln functions via the com plex glutamine/glutamateγaminobutyric acid cycle (GGC), where Gln efflux from astrocytes must be met by its influx in neurons. After exocytotic release at synaptic terminals, glutamate (Glu) is tak en up by surrounding astrocytes via the glia specific Glu transporter 1 GLT1 and the Gluaspartate trans porter GLAST [29, 43] . In astrocytes Glu is converted to Gln by glutamine synthetase (GS). Astrocytic Gln transporters with the predominant role of SNAT3 (system N) mediate its release into the extracellular space. In turn, Gln is transferred into the neurons mainly by SNAT1 and SNAT2 transporters belonging to system A. In neurons Gln is catalyzed to Glu via phosphatedependent glutaminase (PAG). Glutamate is subsequently converted into GABA via decarboxy lation by glutamic acid decarboxylase (GAD). In both astrocytes and neurons Glu is used for the synthesis of alphaketoglutaric acid, a substrate for the tricar boxylic acid cycle, by oxidative deamination medi ated by Glu dehydrogenase (GDH) [3] . Furthermore, Glu is stored in synaptic vesicles at presynaptic termi nals by the vesicular glutamate transporters VGluT1, VGluT2 and VGluT3 (SLC17A6, SLC17A7 and SLC17A8, respectively).
The glutamateγaminobutyric acid cycle plays an essential role in recycling the excitatory neurotrans mitter glutamate. High affinity glutamate transport ers play essential roles in removing released gluta mate from the synaptic cleft and for maintaining the extracellular glutamate concentration of the ce re brospinal fluid below neurotoxic levels. Gluta mine transporters mediate uptake and release of glutamine and supply neurons with the primary neu rotransmitter precursor. Disruption of GGC has been reported in numerous pathological conditions, such as epilepsy, cerebral ischemia, AD, PD and mangan ism [3] .
Manganese and glutamine/ glutamate-γ-aminobutyric acid cycle Manganese and glutamine turnover
Studies have established that the effects of Mn inhalation on GGC vary greatly among different mam malian brain regions. For example, in the brain of monkeys exposed to airborne Mn, GS protein levels were found to be altered, with a strong decrease of GS protein expression in the cerebellum and the glo bus pallidus [11] . Monkeys exposed to Mn also had several other alterations including decreased cau date, globus pallidus, olfactory cortex, and cerebellum GLT1 protein, decreased olfactory cortex and cere bellum GLAST protein. Other rodent models of man ganese exposure have also pointed to alterations in GABA and GAD in the caudate and globus pallidus [19, 46] .
Manganese toxicity is associated with disrup tion of critical points in the GGC, such as glutamine translocation and glutamate uptake by astrocytes. In cultured astrocytes, pretreatment with Mn in hi bits the initial net uptake of Gln in a concentrationdepen dent manner. Manganese added directly to astro cytes induces deregulation in the expression of SNAT3, SNAT2, ASCT2 and LAT2 transporters [34] . Corrobo rating the changes in transporter protein expres sion levels, astrocytes treated with Mn displayed a significant decrease in Gln uptake mediat ed by the transport systems N and ASC, and a decrease in Gln efflux mediated by systems N, ASC and L. PKC(s) signaling, with the predominant role of the PKCδ isoform, has been invoked as a potential mechanism leading to transporters inactivation and glial dysfunction in Mnmediated disruption of Gln transport. Manganese exposure has been demon strated to mediate the specific phosphorylation of PKCδ isozyme, and significantly increase PKC(s) activ ity. In addition, astrocytes transfected with shRNA against PKCδ are significantly less sensitive to Mn compared to those transfected with control shRNA [36] . Treatment of primary astrocyte cultures with a PKC(s) stimulator reduces Gln uptake mediated by systems ASC and N, and reduces expression of ASCT2 and SNAT3 protein levels in cell lysates and in plasma membranes [37] . Furthermore, increased binding of PKCδ to ASCT2 and SNAT3 upon exposure to Mn has been identified by a coimmunoprecipitation study. It is noteworthy that both Mnaffected transporters contain putative PKC phosphorylation sites, which are conserved in the human, rat and mouse [28, 30] .
SNAT3 (system N), selectively expressed on as tro cytic processes ensheathing synapses, mediates release of glutamine and supplies neurons with the primary neurotransmitter precursor. Thus, functional integrity of SNAT3 may be a key regulator for the re cy cling of glutamate and GABA. SNAT3 exhibits a highly differential cellular and subcellular localization and the highest sensitivity to Mn exposure among all investigated Gln transporters. A recent in situ study revealed that PKC(s) activation induces phosphor ylation of SNAT3 and regulates its membrane traf ficking and protein degradation [28] . Notably, the study demonstrated that Mndependent PKC activa tion induces hyperubiquitination, and increases the association of SNAT3 with ubiquitinprotein ligase E3, Nedd42 (neuronal precursor cell expressed, develop mentally downregulated 42) in primary culture of astrocytes. In addition, internalization of SNAT3 upon PKCdependent phosphorylation is corroborated by evidence from an Xenopus laevis oocyte model in which PKC activation reduced V max of the Gln uptake activity [4] . Together, this evidence could represent a link of manganese to PKC(s) regulation in the GGC cycle, since phosphorylation by PKC stimulates transporters' internalization and/or ubiquitination and further lysosomal or proteasomal degradation.
Manganese and the glutamate transport system
The Glu transport system is essential for main taining optimal extracellular Glu concentrations that do not activate Glu transporters and receptors. Rap id removal of glutamate from the extracellular space is required for survival and proper neuronal function. Impaired uptake of glutamate by astrocytes medi ates excitotoxicity, slows the synthesis of gluta thione and leaves the brain vulnerable to oxidative damage [24] . Several studies have demonstrated the propensity of Mn to disrupt the Glu transport system and other components of the GGC, leading to both a reduction in Glu uptake and elevation of extra cellular Glu level [23] . Manganese has been widely reported to mediate the impairment of glutamate transporters, GLAST and GLT1 expression and func tion [12, 27] . Furthermore, Chinese hamster ovary cells transfected with GLAST or GLT1 were found to fail to transport Glu after Mn exposure [27] . A recent finding has identified that PKC signaling is involv ed in Mninduced deregulation of Glu turnover [35] . The study revealed that PKC(s) stimulation signifi cantly reduces astrocytic Glu uptake, while treatment with a general PKC(s) inhibitor protects astrocytes from Mninduced deregulation of Glu transport. Interestingly, coimmunoprecipitation studies demon strated association of GLT1, but not GLAST, with the PKCδ and PKCα isoforms and a Mninduced specific increase in PKCδGLT1 interaction [28, 35] . This evi dence combined with findings on Mn's influence on Gln transport is consistent with abnormal GGC cycling function caused by Mn at two key steps, including Gln and Glu transport, via a homologous, PKC(s)depen dent pattern.
A more recent study revealed the important role of the transcription factor Yin Yang 1 (YY1) in Mnme diated disruption of GLT1. Manganese increases YY1 promoter activity and, consequently, its mRNA and protein levels [20] . Manganese enhances YY1 bind ing to its consensus sites in the GLT1 promoter, and, accordingly, mutations of YY1 binding sites attenuate the Mninduced decrease in GLT1 promoter activity, indicating that YY1 is a critical transcriptional medi ator in Mninduced repression of GLT1. Manganese likely activates YY1 via proinflammatory mediators, such as tumor necrosis factor α (TNFα), interleukin (IL)6 and IL1β [13, 14] . TNFα and IL1β are negative regulators of GLT1, and they reduce GLT1 mRNA and protein levels in astrocytes [21, 40, 44] . Recent stud ies have indicated that Mn increases production of TNFα, which, in turn, increases YY1 promoter activi ty, and mRNA and protein levels [20] , suggesting that TNFα mediates Mn effects on reduction of GLT1 expression via YY1 in astrocytes.
Concluding remarks
Manganism has been considered as a metabolic syndrome related to impairment of glutamate trans port and, more recently, the glutamine/glutamate γaminobutyric acid cycle. In vivo and in vitro studies have demonstrated that Mn evokes mitochondrial abnormalities, oxidative/nitrosative stress and mor phological/functional changes of astrocytes, major players of the GGC. Manganese effectively increas es abnormalities in the glutamine metabolism and turnover between glia and neurons. There appear to be common PKC(s) signaling targets of Mn in GGC cycling in glial cells. The astrocytic glutamate and glu tamine transporters may be targeted by these regu latory mechanisms as a response to certain synaptic activity synergistically inhibiting glutamate recycling. The evidence discussed here not only contributes to understanding the mechanism by which Mn disrupts astrocyte function and astrocyteneuron intercom munication but may potentially lead to the develop ment of novel therapeutic interventions in animal models of manganese toxicity.
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